Faculty

Back to Index
James S. Hu, MD
Clinical Associate Professor of Medicine (Clinician Educator)
Medicine
NOR 3440 Health Sciences Campus Los Angeles
+1 323 865 0813

Overview

James Hu, MD, FACP, is the medical director of the Sarcoma Program of USC, and is considered one of the nation’s experts in the disease. Dr. Hu has more than 20 years of clinical experience in medical oncology and brings this acumen to the bedside. Understanding the rarity of sarcoma cancers, Dr. Hu has the breadth of clinical experience as well as the academic discipline to provide each patient with an individualized treatment program. He has collaborated with other national experts to bring clinical trials to USC. He is a member of the Connective Tissue Oncology Society, and has linked the Sarcoma Program of USC with the international collaborative group: Sarcoma Alliance for Research through Collaboration (SARC), to further direct research into sarcoma.

Dr Hu has authored several review articles on sarcoma, in both national and international peer reviewed journals. As a former military commander of a combat support hospital, Dr. Hu has years of experience in the issues surrounding young adult disease and along with Dr. Siegel, is the co-director of the Adolescent and Young Adult program of USC and Children’s Hospital Los Angeles. This program offers specialized services tailored to adolescent and young adult patients who comprise a significant portion of patients diagnosed with sarcomas. Dr Hu and his medical oncology team pride themselves on patient accessibility and are committed to providing comprehensive oncology care to the patient with sarcoma.

Dr. Hu is a local Angeleno, having grown up in the neighborhood surrounding LAC+USC Medical Center. Dr Hu is proud to be a part of USC and grateful for an opportunity to give back to his community.

Awards

Meritorious Service Medal

Keck School of Medicine: Oncology Fellowship Teacher of the Year, 2011

American College of Physicians: Fellow, 2006

Publications

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Aug 22. View in: PubMed

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. View in: PubMed

Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas. J Ultrasound Med. 2015 Aug; 34(8):1489-99. View in: PubMed

Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas. J Ultrasound Med. 2015 Aug; 34(0):1489-99. View in: PubMed

Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):462. View in: PubMed

Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):39. View in: PubMed

Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. View in: PubMed

Powered bySC CTSI